Alzheimer's disease drug development pipeline: 2022

Abstract

Introduction: Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods: We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results: As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirtyseven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion: The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD.

Synthetic PPAR Agonist DTMB Alleviates Alzheimer's Disease Pathology by Inhibition of Chronic Microglial Inflammation in 5xFAD Mice

“…According to Alzheimer's disease drug development pipeline reports in year 2022, T3D-959 is under the phase II clinical trials as therapeutic agents for Alzheimer's disease [56]. Furthermore, telmisartan and losartan are selective PPARγ agonists that are currently under phase 1 and 3 clinical trials, respectively [56]. Especially, losartan decreases Aβ pathology and neuroinflammation in APP/ PS1 mice model [42,57] as an attenuating agent of angiotensin receptor signaling.…”

Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials

“…In this study, we sought to understand the disease stages and therapeutic hypotheses studied in clinical trials conducted in neurodegenerative diseases to date. Current drug development pipelines have been catalogued elsewhere [11][12][13][14] , but we found that none of these reports answered our key questions. First, experimental drugs are often broadly categorized as "disease-modifying" if the hypothesis is one of disease modification, regardless of the quality of that hypothesis.…”

The Role of Glymphatic System in Alzheimer’s and Parkinson’s Disease Pathogenesis

“…Even if the accumulation of Aβ has been considered the primary injury and therapeutic approaches have been targeted towards Aβ removal, the subsequent tau pathology and tau-mediated neurodegeneration suggested that tau pathology can progress independently of Aβ accumulation [ 97 ]. Tau-targeted therapies in alternative to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [ 98 , 99 ].…”